The active ingredient of turmeric (Curcuma longa L.), Curcumin, has been in the focus of biomedical research since many years. Besides its antioxidant and anti-inflammatory activity, Curcumin has also shown promising potential against cancerous diseases. However, many effects were only demonstrated by in vitro experiments and only few data of in vivo experiments exist. A major reason for the insufficient in vivo data is the low oral bioavailability of Curcumin. The aim of the present work was the development of a formulation for the oral delivery of Curcumin. The drug was incorporated into lipid nanoparticles, which were produced by high pressure homogenization. The produced particles were characterized with regard to their particle size and to the physicochemical properties of the lipid and the incorporated Curcumin. Furthermore, an in vitro digestion assay and release experiments were conducted to simulate the fate of the lipid and the drug during oral ingestion.